Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 137, Issue 4, Pages 868-877Publisher
WILEY-BLACKWELL
DOI: 10.1002/ijc.29461
Keywords
neuroblastoma; prognosis; high-risk; R-score
Categories
Funding
- FIS [PI10/15]
- RTICC [RD12/0036/0020]
- Children Cancer Foundation of Sweden
- Swedish Cancer Society
- Swedish Research Council
- BioCARE
- Swedish Foundation for Strategic Research
- CREATE Health
- Strategic Cancer Research Program
- Gunnar Nilsson Foundation
- Malmo University Hospital
- Instituto Carlos III Madrid
- ERDF, Spain
Ask authors/readers for more resources
Several gene expression-based prognostic signatures have been described in neuroblastoma, but none have successfully been applied in the clinic. Here we have developed a clinically applicable prognostic gene signature, both with regards to number of genes and analysis platform. Importantly, it does not require comparison between patients and is applicable amongst high-risk patients. The signature is based on a two-gene score (R-score) with prognostic power in high-stage tumours (stage 4 and/or MYCN-amplified diagnosed after 18 months of age). QPCR-based and array-based analyses of matched cDNAs confirmed cross platform (array-qPCR) transferability. We also defined a fixed cut-off value identifying prognostically differing subsets of high-risk patients on an individual patient basis. This gene expression signature independently contributes to the current neuroblastoma classification system, and if prospectively validated could provide further stratification of high-risk patients, and potential upfront identification of a group of patients that are in need of new/additional treatment regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available